Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A
- PMID: 12727932
- PMCID: PMC154444
- DOI: 10.1172/JCI17061
Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A
Abstract
Cardiac hypertrophy is a common and often lethal complication of arterial hypertension. Atrial natriuretic peptide (ANP) has been postulated to exert local antihypertrophic effects in the heart. Thus, a loss of function of the ANP receptor guanylyl cyclase-A (GC-A) might contribute to the increased propensity to cardiac hypertrophy, although a causative role in vivo has not been definitively demonstrated. To test whether local ANP modulates cardiomyocyte growth, we inactivated the GC-A gene selectively in cardiomyocytes by homologous loxP/Cre-mediated recombination. Thereby we have circumvented the systemic, hypertensive phenotype associated with germline inactivation of GC-A. Mice with cardiomyocyte-restricted GC-A deletion exhibited mild cardiac hypertrophy, markedly increased mRNA expression of cardiac hypertrophy markers such as ANP (fivefold), alpha-skeletal actin (1.7-fold), and beta-myosin heavy chain (twofold), and increased systemic circulating ANP levels. Their blood pressure was 7-10 mmHg below normal, probably because of the elevated systemic levels and endocrine actions of ANP. Furthermore, cardiac hypertrophic responses to aortic constriction were enhanced and accompanied by marked deterioration of cardiac function. This phenotype is consistent with a local function of the ANP/GC-A system to moderate the molecular program of cardiac hypertrophy.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/154444/bin/JCI0317061.f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/154444/bin/JCI0317061.f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/154444/bin/JCI0317061.f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/154444/bin/JCI0317061.f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/154444/bin/JCI0317061.f5.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/154444/bin/JCI0317061.f6.gif)
![Figure 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/154444/bin/JCI0317061.f7.gif)
![Figure 8](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/154444/bin/JCI0317061.f8.gif)
Comment in
-
A friend within the heart: natriuretic peptide receptor signaling.J Clin Invest. 2003 May;111(9):1275-7. doi: 10.1172/JCI18389. J Clin Invest. 2003. PMID: 12727915 Free PMC article. No abstract available.
Similar articles
-
Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide.J Clin Invest. 2005 Jun;115(6):1666-74. doi: 10.1172/JCI23360. J Clin Invest. 2005. PMID: 15931395 Free PMC article.
-
Hypervolemic hypertension in mice with systemic inactivation of the (floxed) guanylyl cyclase-A gene by alphaMHC-Cre-mediated recombination.Genesis. 2004 Aug;39(4):288-98. doi: 10.1002/gene.20056. Genesis. 2004. PMID: 15287002
-
Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure.Cardiovasc Res. 2004 Nov 1;64(2):308-14. doi: 10.1016/j.cardiores.2004.07.004. Cardiovasc Res. 2004. PMID: 15485690
-
The role of natriuretic peptides in cardioprotection.Cardiovasc Res. 2006 Feb 1;69(2):318-28. doi: 10.1016/j.cardiores.2005.10.001. Epub 2005 Nov 10. Cardiovasc Res. 2006. PMID: 16289003 Review.
-
Cardiac and intestinal natriuretic peptides: insights from genetically modified mice.Peptides. 2005 Jun;26(6):1078-85. doi: 10.1016/j.peptides.2004.08.031. Epub 2005 Apr 14. Peptides. 2005. PMID: 15911075 Review.
Cited by
-
Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development.Rev Cardiovasc Med. 2022 May 6;23(5):165. doi: 10.31083/j.rcm2305165. eCollection 2022 May. Rev Cardiovasc Med. 2022. PMID: 39077592 Free PMC article. Review.
-
Ketone Bodies Rescue Mitochondrial Dysfunction Via Epigenetic Remodeling.JACC Basic Transl Sci. 2023 Jul 5;8(9):1123-1137. doi: 10.1016/j.jacbts.2023.03.014. eCollection 2023 Sep. JACC Basic Transl Sci. 2023. PMID: 37791311 Free PMC article.
-
Developmental roles of natriuretic peptides and their receptors.Cells Dev. 2023 Dec;176:203878. doi: 10.1016/j.cdev.2023.203878. Epub 2023 Sep 22. Cells Dev. 2023. PMID: 37742795 Review.
-
The secretome as a biomarker and functional agent in heart failure.J Cardiovasc Aging. 2023 Jul;3(3):27. doi: 10.20517/jca.2023.15. Epub 2023 Jun 9. J Cardiovasc Aging. 2023. PMID: 37484982 Free PMC article.
-
The Natriuretic Peptide System: A Single Entity, Pleiotropic Effects.Int J Mol Sci. 2023 Jun 1;24(11):9642. doi: 10.3390/ijms24119642. Int J Mol Sci. 2023. PMID: 37298592 Free PMC article. Review.
References
-
- de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28:89–94. - PubMed
-
- Drewett JG, Garbers DL. The family of guanylyl cyclase receptors and their ligands. Endocr. Rev. 1994;13:135–162. - PubMed
-
- de Bold AJ, et al. The physiological and pathophysiological modulation of the endocrine function of the heart. Can. J. Physiol. Pharmacol. 2001;79:705–714. - PubMed
-
- Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML. Diverse biological actions of atrial natriuretic peptide. Pharmacol. Rev. 1990;70:665–699. - PubMed
-
- Murthy KS, et al. G(i-1)/G(i-2)-dependent signaling by single-transmembrane natriuretic peptide clearance receptor. Am. J. Physiol. 2000;278:G974–G980. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous